The role of CXCL11 as a biomarker in RCC patients has also been poorly studied and our findings showing an association with a response to sunitinib and/or pazopanib may encourage future studies to evaluate this chemokine as a possible predictor of response to TKIs. This evidence concerns the gene CXCL11 and renal cell carcinoma.